ArticleJournal of neuro-oncology2014
Local control after fractionated stereotactic radiation therapy for brain metastases.
Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03726359 (Phase I TITE-CREM Dose Escalation Study of Fractionated Stereotactic Radiation Therapy), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I TITE-CREM Dose Escalation Study of Fractionated Stereotactic Radiation Therapy (FSRT) in Unresected Brain Metastases
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fractionated stereotactic radiation therapy for brain metastases: a systematic review with tumour control probability modelling.The British journal of radiology · 2017Pooled it
- Comparison of 3 vs 5 Fraction Single Isocenter Radiosurgery for Brain Metastases.Advances in radiation oncology · 2026Article
- Linear accelerator-based stereotactic radiotherapy for brain metastases, including multiple and large lesions, carries a low incidence of acute toxicities: a retrospective analysis.Radiation oncology (London, England) · 2023Article
- Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma.Frontiers in oncology · 2022Review
- Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.Cancers · 2021Review
- CyberknifeJournal of cancer research and clinical oncology · 2021Article
- Single-fraction versus hypofractionated gamma knife radiosurgery for small metastatic brain tumors.Clinical & experimental metastasis · 2021Article
- Hypofractionated and single-fraction radiosurgery for brain metastases with sex as a key predictor of overall survival.Scientific reports · 2021Article
- Brain metastases from primary colorectal cancer: is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO).The British journal of radiology · 2020Article
- Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study.Clinical & experimental metastasis · 2020Article
- Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.Journal of cancer research and clinical oncology · 2020Review
- Impact of adjuvant fractionated stereotactic radiotherapy dose on local control of brain metastases.Journal of neuro-oncology · 2019Article
- Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BEDJournal of neuro-oncology · 2018Article
- The Expanding Role of Radiosurgery for Brain Metastases.Medicines (Basel, Switzerland) · 2018Review
- Volumetric trends of progressive in-field recurrences after stereotactic radiosurgery of metastatic intracranial tumors.Journal of radiosurgery and SBRT · 2018Article
- Hypofractionated Radiation Therapy for Large Brain Metastases.Frontiers in oncology · 2018Review
- Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.The British journal of radiology · 2017Article
- The radiosurgery fractionation quandary: single fraction or hypofractionation?Neuro-oncology · 2017Article
- Updates in the management of brain metastases.Neuro-oncology · 2016Review
- Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection.Radiation oncology (London, England) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic radiosurgery (SRS) is frequently used in the management of brain metastases, but concerns over potential toxicity limit applications for larger lesions or those in eloquent areas. Fractionated stereotactic radiation therapy (SRT) is often substituted for SRS in these cases. We retrospectively analyzed the efficacy and toxicity outcomes of patients who received SRT at our institution. Seventy patients with brain metastases treated with SRT from 2006-2012 were analyzed. The rates of local and distant intracranial progression, overall survival, acute toxicity, and radionecrosis were determined. The SRT regimen was 25 Gy in 5 fractions among 87 % of patients. The most common tumor histologies were non-small cell lung cancer (37 %), breast cancer (20 %) and melanoma (20 %), and the median tumor diameter was 1.7 cm (range 0.4-6.4 cm). Median survival after SRT was 10.7 months. Median time to local progression was 17 months, with a local control rate of 68 % at 6 months and 56 % at 1 year. Acute toxicity was seen in 11 patients (16 %), mostly grade 1 or 2 with the most common symptom being mild headache. Symptomatic radiation-induced treatment change was seen on follow-up MRIs in three patients (4.3 %). SRT appears to be a safe and reasonably effective technique to treat brain metastases deemed less suitable for SRS, though dose intensification strategies may further improve local control.
Indexed as
Identifiers
25059451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.